Comparison of Wave Life Sciences Ltd. (WVE) and Puma Biotechnology Inc. (NASDAQ:PBYI)

Both Wave Life Sciences Ltd. (NASDAQ:WVE) and Puma Biotechnology Inc. (NASDAQ:PBYI) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Wave Life Sciences Ltd. 11.70M 104.87 139.61M -4.86 0.00
Puma Biotechnology Inc. 201.52M 5.05 146.96M -3.90 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Wave Life Sciences Ltd. and Puma Biotechnology Inc.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Wave Life Sciences Ltd. and Puma Biotechnology Inc.

Net Margins Return on Equity Return on Assets
Wave Life Sciences Ltd. -1,193.25% -112.2% -55%
Puma Biotechnology Inc. -72.93% -301.5% -74.1%

Liquidity

The current Quick Ratio of Wave Life Sciences Ltd. is 1.9 while its Current Ratio is 1.9. Meanwhile, Puma Biotechnology Inc. has a Current Ratio of 3 while its Quick Ratio is 3. Puma Biotechnology Inc. is better positioned to pay off its short-term and long-term debts than Wave Life Sciences Ltd.

Institutional & Insider Ownership

Wave Life Sciences Ltd. and Puma Biotechnology Inc. has shares owned by institutional investors as follows: 82.3% and 95.8%. About 0.4% of Wave Life Sciences Ltd.’s share are owned by insiders. Insiders Comparatively, owned 11.3% of Puma Biotechnology Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Wave Life Sciences Ltd. 1.07% 6.8% -7.8% -0.19% 32.31% 37.78%
Puma Biotechnology Inc. 3.83% 4.59% -49.57% -50.45% -77.02% -75.59%

For the past year Wave Life Sciences Ltd. has 37.78% stronger performance while Puma Biotechnology Inc. has -75.59% weaker performance.

WAVE Life Sciences Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in HuntingtonÂ’s disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In HuntingtonÂ’s disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company has a research, license, and option agreement with Pfizer Inc. for the discovery, development, and commercialization of stereopure oligonucleotide therapeutics; and research collaboration with nLife Therapeutics S.L. exploring cell-specific targeting of nucleic-acid therapeutics in the central nervous system. WAVE Life Sciences Ltd. was founded in 2012 and is based in Cambridge, Massachusetts.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.